Loading clinical trials...
Loading clinical trials...
Age-related macular degeneration (AMD) is one of primary blinding eye disease among people over 65 years in China. The anti-VEGF antibody treatment is proved useful for Neovascular Age-related Macular...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peking University People's Hospital
NCT07328776 · Exudative Age-Related Macular Degeneration, DME, and more
NCT05447650 · Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, and more
NCT04200248 · Exudative Age-related Macular Degeneration
NCT05703867 · Age-Related Macular Degeneration, Nonexudative Age-related Macular Degeneration
NCT02348359 · Age-Related Macular Degeneration (AMD), Macular Degeneration, and more
Xiaoxin Li
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions